Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 5, 2018

Popular Myeloma Drug Associated With Higher Rates of Heart Toxicity

Author(s):

Brielle Benyon

A drug commonly used to treat patients with multiple myeloma may lead to an increased risk of cardiovascular events such as heart attacks, according to recent research conducted at the Abramson Cancer Center of the University of Pennsylvania.

A drug commonly used to treat patients with multiple myeloma may lead to an increased risk of cardiovascular events such as heart attacks, according to recent research conducted at the Abramson Cancer Center of the University of Pennsylvania.

The researchers reviewed 24 studies to collect data on more than 2,500 patients with myeloma. For those prescribed Kyprolis (carfilzomib), one of three FDA-approved proteasome inhibitors, 18 percent experienced a cardiovascular adverse event (CVAE), which included hypertension, heart failure, heart attacks or arrhythmia. Even more alarming is that 8.2 percent of these patients experienced severe CVAEs.

Researchers compared patients on Kyprolis to those who were on Velcade (bortezomib), another FDA-approved proteasome inhibitor, and found that in the latter group, only 3.8 percent of patients experienced CVAEs, and 2.3 percent were severe.

The mechanism of action behind Kyprolis that leads to cardiac events is not yet understood, said study author Adam J. Waxman, M.D., a Hematology Oncology fellow in the Perelman School of Medicine at the University of Pennsylvania.

“I would not call these findings alarming, but rather informative,” Waxman said in an interview with CURE.

According to previous studies, about two-thirds of patients diagnosed with multiple myeloma also have cardiovascular disease, and about 70 percent experienced a cardiovascular event within the past six years. This is because cardiovascular disease and myeloma share some common risk factors, such as old age and obesity.

“Studying cardiovascular adverse events in patients with multiple myeloma is particularly complex because there is a high rate of comorbid cardiovascular disease, patients often receive multiple drugs at the same time and the symptoms of cardiovascular disease may overlap with the other symptoms of multiple myeloma,” Waxman said.

The most common CVAEs included hypertension (12.2 percent), heart failure (4.1 percent) arrhythmias (2.4 percent) and ischemic events (1.8 percent), where there is not enough blood flow to the heart, resulting in death of the muscle.

Patients prescribed Kyprolis should work with their health care team to spot early signs of cardiovascular toxicities. These can include high blood pressure, new onset of shortness of breath with exertion or leg edema.

Waxman did note that CVAEs can be reversible or better prevented with appropriate cardiovascular therapies. And, since the majority of patients with myeloma will likely be prescribed Kyprolis at some point in their treatment, it is crucial that patients don’t panic at these findings, and still realize that the drug may be a viable treatment option.

“Whether the benefit outweighs the risk will always be a very personalized question to discuss between patients and their oncologists, especially in the context of other available options,” Waxman said. “However, an effective treatment for an incurable malignancy will always have an important benefit associated with it, though where in the course of treatment it should be used is an area of investigation.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of doctor with grey hair.
Dr. Mikhael in an interview with CURE
Dr. Ajai Chari in an in interview with CURE
An image of Dr. Patel in an interview with CURE discussing healthy lifestyles in myeloma
Dr. Munshi in an interview with CURE
Dr. Dikran Kazandjian during an interview with CURE
Related Content
Advertisement
Ronald Chin received a diagnosis of multiple myeloma in January 2017 and has been in remission since October 2023. Catch up on all of Ronald's blogs here!
May 13th 2025

I Found Strength After Surviving Multiple Myeloma and Through Recovery

Ronald Chin
I share how I survived multiple myeloma, painful spine fractures and years of recovery to reclaim my independence and vitality.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Blood cells.
May 7th 2025

Cemsidomide Generates Results at Multiple Doses in Multiple Myeloma

Ryan Scott
Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Image of plasma cells.
April 4th 2025

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

Spencer Feldman
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.
Dr. Surbhi Sidana discussed the topic of minimal residual disease: nobeastsofierce - stock.adobe.com
April 1st 2025

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

Alex Biese
Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.
Related Content
Advertisement
Ronald Chin received a diagnosis of multiple myeloma in January 2017 and has been in remission since October 2023. Catch up on all of Ronald's blogs here!
May 13th 2025

I Found Strength After Surviving Multiple Myeloma and Through Recovery

Ronald Chin
I share how I survived multiple myeloma, painful spine fractures and years of recovery to reclaim my independence and vitality.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Blood cells.
May 7th 2025

Cemsidomide Generates Results at Multiple Doses in Multiple Myeloma

Ryan Scott
Treatment with cemsidomide resulted in notable responses at multiple dose levels for patients with multiple myeloma
Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic
January 13th 2022

Health Care Worker Discusses Cancer Diagnosis and Vaccine Experience While on the Frontlines of the COVID-19 Pandemic

Jamie Cesanek
In this episode of the “Cancer Horizons” podcast, a physician assistant recalls his experience as a frontline health care worker during the COVID-19 pandemic and what it was like to get diagnosed with multiple myeloma during such a chaotic time.
Image of plasma cells.
April 4th 2025

Overcoming Challenges and Advancing CAR-T Therapy for Myeloma

Spencer Feldman
CAR-T therapy for myeloma faces challenges in early-line use due to accessibility, eligibility criteria and long wait times, despite strong efficacy in trials.
Dr. Surbhi Sidana discussed the topic of minimal residual disease: nobeastsofierce - stock.adobe.com
April 1st 2025

What Role Does MRD Play in Multiple Myeloma Treatment Decision Making?

Alex Biese
Dr. Surbhi Sidana discussed the topic of minimal residual disease during the CURE Educated Patient® Multiple Myeloma Summit.
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.